论文部分内容阅读
目的探讨脑恶性胶质瘤长期生存患者的主要治疗方法和安全性。方法比较分析5例经病理组织学证实的脑恶性胶质瘤长期生存患者的临床资料。结果尤以术后同步放化疗(卡莫司汀或紫杉醇)为主的治疗方法,患者的生存时间长,可达7年以上,且毒副反应轻微。结论术后同步放化疗对脑恶性胶质瘤患者具有潜在的治疗价值,并很少增加毒性反应。
Objective To investigate the main treatment and safety of patients with long-term survival of malignant gliomas. Methods The clinical data of 5 patients with long-term survival of malignant gliomas confirmed by histopathology were analyzed. The results of postoperative concurrent chemoradiation (carmustine or paclitaxel) based treatment, patients with long survival time, up to 7 years, and minor toxicities. Conclusions Concurrent concurrent chemoradiotherapy has potential therapeutic value for patients with glioblastoma and rarely increases toxicity.